Volumes increased by 5% year on year in Q3, reaching a new record high. Exceptional EBIT increase for the quarter driven mainly by margin increase in the Salmon segment, reflecting both temporary market conditions and our ability to actively manage raw material volatility. While part of the performance is not expected to persist at the same level going forward, our capabilities in optimising formulations and maintaining the nutritional performance provided value to our customers and BioMar. With the updated market development for the remainder of the year and with the strong earnings performance so far in 2026, BioMar has raised its revenue and EBIT guidance for 2026.